David Davidson Net Worth

The estimated Net Worth of David Davidson is at least $6.9 Million dollars as of 5 April 2021. David Davidson owns over 42 units of Bluebird bio Inc stock worth over $27,716 and over the last 11 years he sold BLUE stock worth over $1,645,072. In addition, he makes $5,229,030 as Chief Medical Officer at Bluebird bio Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Davidson BLUE stock SEC Form 4 insiders trading

David has made over 94 trades of the Bluebird bio Inc stock since 2013, according to the Form 4 filled with the SEC. Most recently he sold 42 units of BLUE stock worth $1,269 on 5 April 2021.

The largest trade he's ever made was exercising 22,000 units of Bluebird bio Inc stock on 2 April 2018 worth over $538,340. On average, David trades about 3,959 units every 27 days since 2013. As of 5 April 2021 he still owns at least 47,787 units of Bluebird bio Inc stock.

You can see the complete history of David Davidson stock trades at the bottom of the page.

David Davidson biography

Dr. David M. Davidson M.D. serves as Chief Medical Officer of the Company. Dr. Davidson has served as our Chief Medical Officer since February 2012. Prior to joining us, Dr. Davidson served as a senior medical director at Genzyme Corporation, where he led clinical research for programs in Phases I through IV across a wide range of therapeutic areas for more than a decade. Most recently, Dr. Davidson was the medical leader for Genzyme’s gene therapy and Pompe disease enzyme replacement therapy programs. In addition to Dr. Davidson’s translational medicine experience, he has also worked on a number of commercial products, including Fabrazyme and Myozyme/Lumizyme, and was integral in crafting the new drug application that resulted in the approval of Welchol. Prior to Genzyme, Dr. Davidson was a medical director at GelTex Pharmaceuticals Inc. Previously, he completed clinical and research fellowships in infectious diseases at the Harvard Longwood Combined Infectious Diseases Program. Dr. Davidson received his B.A. from Columbia University and his M.D. from New York University School of Medicine. In addition, he completed an internal medicine internship, residency training and an endocrinology research fellowship at the University of Chicago Hospitals.

What is the salary of David Davidson?

As the Chief Medical Officer of Bluebird bio Inc, the total compensation of David Davidson at Bluebird bio Inc is $5,229,030. There are 2 executives at Bluebird bio Inc getting paid more, with Nick Leschly having the highest compensation of $13,153,600.

How old is David Davidson?

David Davidson is 56, he's been the Chief Medical Officer of Bluebird bio Inc since 2012. There are 6 older and 15 younger executives at Bluebird bio Inc. The oldest executive at Bluebird bio Inc is Wendy Dixon, 64, who is the Independent Director.

What's David Davidson's mailing address?

David's mailing address filed with the SEC is C/O BLUEBIRD BIO, INC., 60 BINNEY STREET, CAMBRIDGE, MA, 02142.

Insiders trading at Bluebird bio Inc

Over the last 11 years, insiders at Bluebird bio Inc have traded over $130,743,125 worth of Bluebird bio Inc stock and bought 6,469 units worth $399,874 . The most active insiders traders include Steven Gillis, John Maraganore und Robert I Tepper. On average, Bluebird bio Inc executives and independent directors trade stock every 8 days with the average trade being worth of $6,033. The most recent stock trade was executed by Thomas J Klima on 3 June 2024, trading 3,834 units of BLUE stock currently worth $3,719.

What does Bluebird bio Inc do?

we are leading the gene therapy revolution. our integrated product platforms encompass gene therapy, cancer immunotherapy and gene editing – providing us with the potential to treat, and hopefully cure, a broad range of serious diseases. we have a lot of energy, and it’s not just the abundance of coffee that keeps us going. find out what sparks our excitement and inspires us every day.

Complete history of David Davidson stock trades at Bluebird bio Inc

Bluebird bio Inc executives and stock owners

Bluebird bio Inc executives and other stock owners filed with the SEC include:

• Nick Leschly,
  President, Chief Executive Officer, Director
• William Baird,
  Chief Financial Officer
• David Davidson,
  Chief Medical Officer
• Philip Gregory,
  Chief Scientific Officer
• Jason Cole,
  Chief Operating Officer and Legal Officer, Secretary
• Nick Leschly,
  Pres & Director
• William Sellers,
  Independent Director
• William D. Baird III,
  Principal Financial & Accounting Officer
• Daniel Lynch,
  Independent Chairman of the Board
• Jason F. Cole Esq.,
  Chief Strategy & Financial Officer
• Thomas J. Klima,
  Chief Commercial Officer & COO
• Mark Vachon,
  Independent Director
• David Schenkein,
  Independent Director
• Wendy Dixon,
  Independent Director
• John Agwunobi,
  Independent Director
• Ingrid Goldberg,
  VP, Investor Relations
• Denice Torres,
  Director
• Joanne Smith-Farrell,
  Chief Business Officer
• Alison Finger,
  Chief Commercial Officer
• Katy Burnett,
  Interim Principal Accounting Officer
• Richard Colvin M.D., Ph.D.,
  Chief Medical Officer
• Andrea Walton,
  Chief People Officer
• Katherine Edna Breedis C.F.A., CMT,
  Interim CFO, Principal Financial Officer & Principal Accounting Officer
• Anne-Virginie Eggimann M.Sc.,
  Chief Regulatory Officer
• Melissa Bonner,
  Sr. VP of Research
• Dr. Liviu Niculescu M.D., Ph.D.,
  Sr. VP of Global Medical Affairs
• Sarah Alspach,
  Chief Communications Officer
• Kathleen A. Wilkinson,
  Chief People Officer
• Elizabeth Pingpank,
  Director of Corp. Communications
• Helen C. Fu,
  Sr. VP, Gen. Counsel & Sec.
• Jessica Whitten,
  VP, Global Controller & Chief Accounting Officer
• Kasra Kasraian,
  Sr. VP of Technical Devel. & Operations
• Gina R. Consylman CPA,
  Chief Financial Officer
• Andrew Obenshain,
  Pres, CEO & Director
• John Maraganore,
  Director
• James Mandell,
  Director
• Susanna Gatti High,
  Chief Operating Officer
• Eric Sullivan,
  Principal Accounting Officer
• Andrew Obenshain,
  President and CEO
• Douglas Melton,
  
• Mary Lynne Hedley,
  Director
• Kory James Wentworth,
  Principal Accounting Officer
• Thomas J Klima,
  See Remarks
• Charlotte Jones Burton,
  
• Axel Polack,
  Director
• Geert Jan Mulder,
  Director
• Christopher Krawtschuk,
  Chief Financial Officer
• Mitchell H. Finer,
  Chief Scientific Officer
• James M. Detore,
  Chief Financial Officer
• Venture Fund Vii Lparch Ven...,
  
• Robert I Tepper,
  Director
• Rock Ventures Lptrv Gp, Llc...,
  
• Linda Bain,
  VP, Fin. & Business Operations
• Rock Ventures Lp Third Rock...,
  
• Jeffrey T. Walsh,
  Chief Strategy Officer
• Steven Gillis,
  Director
• Richard A. Paulson,
  
• Gina Consylman,
  Chief Financial Officer
• Anne Virginie Eggimann,
  Chief Regulatory Officer
• Jessica Whitten,
  Chief Accounting Officer
• Marcela V. Maus,
  Director
• Sarah Js Glickman,
  Director
• Ramy Ibrahim,
  Director
• Joseph Vittiglio,
  Chief Business & Legal Officer
• Richard A Colvin,
  Chief Medical Officer
• Najoh Tita Reid,
  
• Elisabeth Leiderman,
  
• Michael Cloonan,
  
• O. James Sterling,
  Chief Financial Officer